Skip to main content
logo
Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.97
-0.11 (-0.72%)
Jan 22, 2026, 2:57 PM EST - Market open

Revenue Breakdown

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Gastroenterology Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Rare Metabolic Revenue
--
Log In
Log In
Log In
Upgrade
Rare Hematology Revenue
--
Log In
Log In
Log In
Upgrade
Hereditary Angioedema Revenue
--
Log In
Log In
Log In
Upgrade
Other Rare Disease Revenue
--
Log In
Log In
Log In
Upgrade
Rare Genetics and Other Revenue
--
Log In
Log In
Log In
Upgrade
Total Rare Diseases Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
PDT Immunology Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Oncology Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Other Product Revenue (Pre-FY2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.47T4.58T
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
GI Revenue (Post-FY2024 Reporting)
1.35T1.36T
Log In
Log In
Log In
Upgrade
Rare Diseases Revenue (Post-FY2024 Reporting)
744.60B752.82B
Log In
Log In
Log In
Upgrade
PDT Revenue (Post-FY2024 Reporting)
1.01T1.03T
Log In
Log In
Log In
Upgrade
Oncology Revenue (Post-FY2024 Reporting)
563.30B560.43B
Log In
Log In
Log In
Upgrade
Vaccines Revenue
49.00B55.41B
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Post-FY2024 Reporting)
457.30B565.82B
Log In
Log In
Log In
Upgrade
Other Product Revenue (Post-FY2024 Reporting)
233.70B257.39B
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.47T4.58T
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Japan Revenue
421.20B418.46B
Log In
Log In
Log In
Upgrade
United States Revenue
2.22T2.38T
Log In
Log In
Log In
Upgrade
Europe and Canada Revenue
1.06T1.06T
Log In
Log In
Log In
Upgrade
Latin America Revenue
221.80B235.85B
Log In
Log In
Log In
Upgrade
China Revenue
-191.74B
Log In
Log In
Log In
Upgrade
Asia (ex-Japan & China) Revenue
97.30B99.39B
Log In
Log In
Log In
Upgrade
Asia (ex-Japan) Revenue
291.50B291.13B
Log In
Log In
Log In
Upgrade
Russia / CIS Revenue
72.60B72.36B
Log In
Log In
Log In
Upgrade
Other Geographic Revenue
128.50B128.85B
Log In
Log In
Log In
Upgrade
Revenue (Other)
53.21B1.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.47T4.58T
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.